Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study

Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study

Background: In the global Phase-3 Selective Prostate Androgen Receptor Targeting with ARN-509 study, apalutamide plus ongoing androgen deprivation therapy (ADT) significantly increased metastasis-free survival (MFS) and improved other clinical outcomes in men with nonmetastatic castration-resistant...

Full description

Bibliographic Details
Main Authors: Hiroji Uemura, Takefumi Satoh, Hideyasu Tsumura, Gaku Arai, Keiichiro Imanaka, Kazuhiro Shibayama, Koji Fujii, Brendan Rooney, Angela Lopez-Gitlitz, Byron Espina, Carlos Perez-Ruixo, Eric J. Small, Matthew Smith
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Prostate International
Subjects:
Apalutamide
Metastasis-free survival
Nonmetastatic castration-resistant prostate cancer
Prostate-specific antigen
Online Access:http://www.sciencedirect.com/science/article/pii/S2287888220300301

Internet

http://www.sciencedirect.com/science/article/pii/S2287888220300301

Similar Items